Hyo Jung An1, Hyun Min Koh1, Dae Hyun Song2,3,4. 1. Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea. 2. Department of Pathology, Gyeongsang National University Changwon Hospital, Changwon, Republic of Korea golgy@hanmail.net. 3. Gyeongsang National University School of Medicine, Jinju, Republic of Korea. 4. Gyeongsang Institute of Health Science, Jinju, Republic of Korea.
Abstract
BACKGROUND: There have been many attempts to predict the prognosis of lung cancer based on the expression patterns of P16 protein, but with limited success. The Eighth American Joint Committee on Cancer (AJCC) for head and neck cancer recently developed new criteria for evaluating P16 expression. Here, we applied these new criteria to evaluate the prognosis of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: A total of 148 patients who had undergone surgery for NSCLC were enrolled in the study. P16 protein expression patterns from NSCLC tissue microarray samples were examined by immunohistochemical analysis. The Eighth AJCC head and neck cancer staging criteria were used to evaluate positive P16 expression (moderate/strong nuclear expression intensity and distribution >75% cells) in NSCLC. The relationship between P16 expression and clinicopathological factors were evaluated and survival analysis was included. RESULTS: Negative P16 expression was significantly associated with NSCLC with lymph node metastasis (p=0.025). In addition, patients with NSCLC with negative P16 expression demonstrated poor disease-free and disease-specific survival in multivariate analysis. The Kaplan-Meier survival curve confirmed that negative P16 expression was significantly correlated with a poor disease-free survival (p=0.017) and disease-specific survival (p=0.016). CONCLUSION: P16 expression defined with the new AJCC criteria is useful for detecting lymph node metastasis in NSCLC. Copyright
BACKGROUND: There have been many attempts to predict the prognosis of lung cancer based on the expression patterns of P16 protein, but with limited success. The Eighth American Joint Committee on Cancer (AJCC) for head and neck cancer recently developed new criteria for evaluating P16 expression. Here, we applied these new criteria to evaluate the prognosis of non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: A total of 148 patients who had undergone surgery for NSCLC were enrolled in the study. P16 protein expression patterns from NSCLC tissue microarray samples were examined by immunohistochemical analysis. The Eighth AJCC head and neck cancer staging criteria were used to evaluate positive P16 expression (moderate/strong nuclear expression intensity and distribution >75% cells) in NSCLC. The relationship between P16 expression and clinicopathological factors were evaluated and survival analysis was included. RESULTS: Negative P16 expression was significantly associated with NSCLC with lymph node metastasis (p=0.025). In addition, patients with NSCLC with negative P16 expression demonstrated poor disease-free and disease-specific survival in multivariate analysis. The Kaplan-Meier survival curve confirmed that negative P16 expression was significantly correlated with a poor disease-free survival (p=0.017) and disease-specific survival (p=0.016). CONCLUSION:P16 expression defined with the new AJCC criteria is useful for detecting lymph node metastasis in NSCLC. Copyright
Authors: Gaetano Rocco; Katie Nason; Alex Brunelli; Gonzalo Varela; Thomas Waddell; David R Jones Journal: Eur J Cardiothorac Surg Date: 2016-04 Impact factor: 4.191
Authors: Robert A A van Boerdonk; Johannes M A Daniels; Elisabeth Bloemena; Oscar Krijgsman; Renske D M Steenbergen; Ruud H Brakenhoff; Katrien Grünberg; Bauke Ylstra; Chris J L M Meijer; Egbert F Smit; Peter J F Snijders; Daniëlle A M Heideman Journal: J Thorac Oncol Date: 2013-06 Impact factor: 15.609
Authors: Nicolas F Schlecht; Margaret Brandwein-Gensler; Gerard J Nuovo; Maomi Li; Anne Dunne; Nicole Kawachi; Richard V Smith; Robert D Burk; Michael B Prystowsky Journal: Mod Pathol Date: 2011-05-13 Impact factor: 7.842
Authors: Jinyoung Yoo; Ji Han Jung; Myung A Lee; Kyung Jin Seo; Byoung Yong Shim; Sung Hwan Kim; Deog Gon Cho; Myeong Im Ahn; Chi Hong Kim; Kyu Do Cho; Seok Jin Kang; Hoon Kyo Kim Journal: J Korean Med Sci Date: 2007-04 Impact factor: 2.153
Authors: Young Seoub Hong; Mee Sook Roh; Na Young Kim; Hye Jung Lee; Hee Kyoung Kim; Kyung Eun Lee; Jong Young Kwak; Joon Youn Kim Journal: J Korean Med Sci Date: 2007-09 Impact factor: 2.153